Jazz pharmaceuticals stock

Who buys Jazz Pharmaceuticals (jazz)? JAZZ stock was purchased in the quarter by several institutional investors, including the Alaska Department of Revenue, the New Mexico State Board of Pensions and Confluence Investment Management LLC. Get insider information on how to buy and sell Jazz Pharmaceuticals, or check out the most popular insider buys.

What are Wall Street's price targets for Jazz Pharmaceuticals' shares?

Thirteen Wall Street analysts have released 12-month forecasts for Jazz Pharmaceuticals stock. Their forecasts range from $ to $ on average and they expect shares of Jazz Pharmaceuticals to climb to $ $ over the next 12 months. This indicates a possible increase in the current price of the stock.

What does the company justjazz Pharmaceuticals plc do?

Jazz Pharmaceuticals Plc is a biopharmaceutical company focused on the identification, development and commercialization of drugs for the treatment of narcolepsy, oncology, pain relief and psychiatry. The product range includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio and Zepzelca.

What are the earnings earnings for advancedjazz Pharmaceuticals plc (jazz)?

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced its quarterly results on Tuesday, Aug. 3. The specialty pharmaceutical company reported earnings per share in US dollars for the quarter, beating analyst consensus estimates in US dollars per US dollar.

What are analysts' target prices for Jazz Pharmaceuticals' stock?

15 Wall Street analysts have posted annual price targets for Jazz Pharmaceuticals stock. Your forecast varies between $ and $. On average, they expect Jazz Pharmaceuticals' stock price to hit $100 in the next year.

What is the upside for Jazz Pharmaceuticals (jazz) stock?

On average, they expect Jazz Pharmaceuticals shares to hit the dollar over the next 12 months. This indicates a possible increase in the current price of the stock. Check out Jazz Pharmaceuticals' analyst target prices or check out the top-rated stocks from Wall Street analysts.

How do 6060 employees rate Jazz Pharmaceuticals CEO?

Bruce K. Cozadd, CEO of Jazz Pharmaceuticals, was rated Bruce K. by 60 employees. Cozadd has a 92% approval rating among Jazz Pharmaceuticals employees. This places Bruce K. Cozadd in the top 30% of approval ratings compared to other public company CEOs. Who are Jazz Pharmaceuticals' main competitors?

Where can I buy shares of jazz?

JAZZ shares can be purchased through any online brokerage account. Popular online stock brokers include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare the best brokers here.

Where is the headquarters of justjazz pharmaceuticals?

Jazz Pharmaceuticals is located at FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04.

What does the company Jazz Pharmaceuticals do?

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company committed to innovation to change the lives of patients and their families. They are committed to developing life-changing drugs for people with serious medical conditions, often with limited or no treatment options.

How do I contact jazz about a job listing?

For job opportunities, contact @ Jazz Pharmaceuticals plc (NASDAQ: JAZZ), a global biopharmaceutical company dedicated to innovation to transform the lives of patients and their families.

Why jazz medicine?

Jazz's goal is to develop life-changing medicines for people with serious medical conditions, often with or without disabilities, so that they can live better lives and support their patient community in their well-being.

When did Jazz Pharmaceuticals buy GW Pharmaceuticals?

In January 2021, Jazz announced it would acquire GW Pharmaceuticals for $1 billion (in cash and Jazz stock). The following is an illustration of the company's major mergers and acquisitions and their historical predecessors (this is not a complete list):.

How many employees does justjazz pharmaceuticals have?

Jazz Pharmaceuticals has 1,940 employees. What are Jazz Pharmaceuticals' sales? Jazz Pharmaceuticals had billions of dollars in sales last year. What is Jazz Pharmaceuticals' revenue per employee?

Does Jazz Pharmaceuticals own Vyxeos?

This gave Jazz the rights to the groundbreaking Vyxeos therapy (liposomal daunorubicin and cytarabine) for the treatment of acute myeloid leukemia. In August 2019, the company announced the acquisition of Cavion Inc. for a maximum amount of approximately $310 million.

What does the company just jazz pharmaceuticals plc do food

Jazz Pharmaceuticals is a global biopharmaceutical company committed to providing life-changing medicines to people with limited or no capabilities to help them live better lives.

What has Jazz Pharmaceuticals been up to since its big acquisition?

At the end of that month, the company announced its largest acquisition to date, the $1 billion purchase of Celator Pharmaceuticals. As a result, Jazz acquired the rights to the revolutionary Vyxeos therapy (liposomal daunorubicin and cytarabine) for the treatment of acute myeloid leukemia.

What is the Jazz Association of women supporters doing for women?

In November, the Women's Advocates Jazz Association hosted an engaging virtual Affinity Forum where members could talk about the Women's Alliance and the various actions they can take to protect women and advance their careers.

Who owns Jazz Pharmaceuticals stock?

Company members who own shares in Jazz Pharmaceuticals include Bruce K. Cozadd, Bruce C. Cozadd, Elmar Schnee, Finbar Larkin, James E. Flynn, Kenneth W. Okeefe, Michael Patrick Miller, Patricia Carr, Patrick G. Enright, Paul L. burns. and Seamus Mulligan. See Jazz Pharmaceuticals Institutional Ownership Trends.

When did Jazz Pharmaceuticals buy EUSA Pharma?

On September 19, 2011, Jazz Pharmaceuticals and Azur Pharma PLC agreed to merge. On April 26, 2012, EUSA Pharma acquired EUSA Pharma for $650 million (plus $50 million in partial payments). In September, the company successfully sold its women's health business to Meda for $95 million.

What does the company just jazz pharmaceuticals plc do drugs

(6 days ago) Jazz Pharmaceuticals Plc is a biopharmaceutical company engaged in the discovery, development and commercialization of pharmaceutical products in the fields of narcolepsy, oncology, pain and psychiatry. Category: Pharmaceutical Drugs Retail Jazz Pharmaceuticals.

Why choose Jazz Sleep Medicine?

As a long-time leader in the sleep medicine market, Jazz is at the forefront of therapy and support for patients with severe and debilitating neurological disorders.

Why does jazz prioritize developing new medicines where others don't?

They prioritize the development of new medicines where others have not, for the benefit of people with disabilities. Most of the disease areas that Jazz focuses on either lacked adequate treatment options or had limited effective treatment options until they were developed or made available. Read more about their research and development.

What does the company just jazz pharmaceuticals plc do medical

About Jazz Pharmaceuticals Jazz Pharmaceuticals Plc is a biopharmaceutical company focused on the identification, development and commercialization of drugs for the treatment of narcolepsy, oncology, pain management and psychiatry. The product range includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio and Zepzelca.

What does the company just jazz pharmaceuticals plc do good

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company committed to innovation to change the lives of patients and their families. They focus on developing life-changing drugs for people with serious illnesses, often with limited or no options, so they can live better lives.

Is Jazz Pharmaceuticals the best stock to buy now?

Wall Street analysts have advised Jazz Pharmaceuticals to buy, but there may be better buying opportunities in the stock market. Some of MarketBeats' previous successful trading ideas have generated weekly gains of 515%. MarketBeat just released five new stock ideas, but Jazz Pharmaceuticals was not one of them.

How did Jazz Pharmaceuticals' earnings compare to analysts' estimates?

The specialty pharmaceutical company made millions of dollars in the quarter, compared to analysts' estimates of millions of dollars. Jazz Pharmaceuticals achieved return on equity and net profit of View Jazz Pharmaceuticals last year. How will the coronavirus affect Jazz Pharmaceuticals' stocks?

What is the earnings guidance for ajjazz pharmaceuticals?

Jazz Pharmaceuticals updated its revenue forecast for fiscal 2021 on Tuesday, August 17. The company posted $$ for the period in earnings per share (EPS), compared to the Thomson Reuters consensus of $$.

Why is jazz pharmaceuticals stock falling

The slump started in the summer when Jazz announced its second-quarter results, which showed sales of its top sleep aid, Xylem, were down 25% year-over-year. Although this was because patients were in the process of transitioning to the next-generation drug, Xywav, overall sales increased by just 3%. Image source: Getty Images.

What is the jazz stock price prediction for 2026-09-07?

Jazz Pharmaceuticals plc is trading in USD for 20210911. According to their forecast long-term growth is expected, JAZZ's share price forecast for 20260907 is in US Dollars.

What is the ticker symbol for Jazz Pharmaceuticals plc?

Jazz Pharmaceuticals is listed on the NASDAQ under the symbol JAZZ. Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) released its quarterly results on Tuesday, Aug. 6. Jazz Pharmaceuticals will publish its earnings report for the next quarter on Tuesday, November 5, 2019.

Is inflation coming to Jazz Pharmaceuticals (jazz)?

Inflation is coming. Buy 5 shares now. Jazz Pharmaceuticals (JAZZ) Beats Earnings Estimates: Could Stocks Rise? Can you buy Jazz Pharmaceuticals stock?